ACTRN12616000603415
Recruiting
未知
The utility of pulmonary function parameters in addition to FEV1 (forced expiratory volume in one second) and FVC (forced vital capacity) and the variability of each for assessing the reversibility of airway obstruction in adults undergoing bronchodilator response testing
aura Ploen0 sites800 target enrollmentMay 10, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- aura Ploen
- Enrollment
- 800
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 18 \- 95 years.
- •Having a bronchodilator response test as part of their visit to the respiratory laboratory.
- •Able to provide informed consent.
Exclusion Criteria
- •Patient has an absolute contraindication to performing spirometry. This includes: recent mycardial infarction, recent eye or thoracic surgery, or any other condition deemed by the testing scientist to put the patient at risk.
- •Patient is unable to perform acceptable spirometry.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Investigating the Pulmonary Function Parameters following Coronary Artery Bypass Surgery in Patients with General Anesthesia and General Anesthesia with Spinal Anesthesiacoronary artery bypass.IRCT20191016045133N1Ahvaz University of Medical Sciences60
Recruiting
Not Applicable
Assessment of localized pulmonary function by multiple pulmonary function test system in patients with respiratory diseaseJPRN-UMIN000040716St. Marianna University School of Medicine50
Not yet recruiting
Not Applicable
Paravertebral vs. Erector Spinae Blocks for lung function in those with rib fracturesACTRN12620001192976Middlemore Hospital40
Active, not recruiting
Not Applicable
The association between various diagnostic measurements and lung functioISRCTN45778591niversity Hospital of Basel20,000
Not yet recruiting
Not Applicable
Assessment of Pulmonary functions in patients receiving radiation therapy for lung cancerCTRI/2021/06/034156TATA MEMORIAL HOSPITA